Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.

Morton FreytagMartina KluthElena BadyClaudia Hube-MaggGeorgia Makrypidi-FrauneHans HeinzerDoris HöflmayerSören WeidemannRia UhligHartwig HulandMarkus GraefenChristian BernreutherCorinna WittmerMaria Christina TsourlakisSarah MinnerDavid DumAndrea HinschAndreas M LuebkeRonald SimonGuido SauterThorsten SchlommKatharina Möller

Published in: BMC cancer (2020)

Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application.

Keyphrases

poor prognosis
prostate cancer
long non coding rna
radical prostatectomy
transcription factor
genome wide
electronic health record
big data
risk assessment
cell proliferation
dna methylation
gene expression
signaling pathway
amino acid
adverse drug
deep learning
drug induced
data analysis